

13<sup>th</sup> February 2019 | CannPal Animal Therapeutics Limited ACN: 612 791 518 |  
ASX:CP1

## ***CannPal Receives Key Ethics Approvals for CPAT-01 Phase 2A study and DermaCann Skin Study***

### **Key Highlights**

- Ethics approval received for CannPal's Phase 2A clinical study for CPAT-01, in development for pain and inflammation control in dogs;
- 60 dogs with osteoarthritis will be recruited from veterinary clinics across NSW & QLD for a randomized, placebo controlled, double-blind study using CPAT-01 at 3 different doses;
- Ethics approval also received to evaluate the safety and efficacy of DermaCann, in development as a skin supplement for dogs;
- 45 dogs with clinical symptoms of dermatitis will be recruited through dermatology specialists in NSW for a double blind, placebo controlled study using DermaCann;
- The Company hopes to complete recruitment for both studies by mid CY2019.

---

**13<sup>th</sup> February 2019:** Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** ("CannPal" or "the Company") is pleased to announce it has received 2 key ethics approvals to progress the research and development of the Company's lead therapeutic products, CPAT-01, a pain and inflammatory control being developed for dogs, and DermaCann, a nutraceutical product in development to promote canine skin health.

### *CPAT-01 Osteoarthritis Study*

The Phase 2A clinical study is a 6 to 8-week randomized, double-blind, placebo controlled, pilot dose determination study to explore the effects of various doses of CPAT-01 in client owned animals with osteoarthritis. Approximately 60 dogs will be enrolled in the study across various veterinary clinics in Australia, with recruitment to commence in H1 2019

CPAT-01 is the Company's lead pharmaceutical product in development for the control of pain and inflammation in dogs, a market estimated to be worth over US\$1b globally. CannPal is developing CPAT-01 as a regulatory approved cannabinoid derived veterinary medicine to be sold by veterinarians in major global markets.

### *DermaCann Skin Study*

The double blind placebo-controlled clinical trial for DermaCann is an 8 week efficacy study designed to explore the effects and confirm safety of the Company's lead nutraceutical product in dogs with skin conditions. Approximately 45 dogs will be enrolled for the study via specialist dermatology hospitals in NSW.

DermaCann is CannPal's lead nutraceutical product being developed as a skin supplement for dogs which includes hemp derived CBD (cannabidiol). The global pet dietary supplement



market for companion animals was worth over US\$1.3B in 2015, expected to reach over US\$1.8B BY 2021 with an estimated US\$440m attributed to skin and coat supplements.

Initially the Company intends to use the results from the upcoming study to prepare a dossier to seek complementary animal health product approval (CAHP) with the APVMA (Australian Pesticides and Veterinary Medicines Authority) to allow for the sale of DermaCann through Australian veterinarians.

***CannPal's Founder and Managing Director Layton Mills:***

"I'm delighted that we're moving into the second Phase for CPAT-01, with-in just a few months of completing our Phase 1 research activities. I'm also pleased that our research and development team has been able to progress the DermaCann project plan with the same momentum via the initiation of our safety and efficacy study, which is a major milestone for our nutraceutical strategy. I'm looking forward to commencing our Phase 2 pilot studies for CPAT-01 and the potential to explore commercialization opportunities for our nutraceutical products in 2019."

***About CannPal Animal Therapeutics***

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals. To learn more please visit: [www.cannpal.com](http://www.cannpal.com)

**ENDS**

---

**For further information, please contact:**

**CannPal**

Layton Mills  
Founder and Managing Director  
M: +61 431 302 667  
E: [layton@cannpal.com](mailto:layton@cannpal.com)



**@CannPalAT**



**facebook.com/CannPal**

